News

Overlooked molecular machine in cell nucleus may hold key to treating aggressive leukemia

Many individuals forced to fight an exceptionally aggressive form of the blood cancer acute myeloid leukemia (AML) don t survive more than five years.

advertisement

The only cure -- a bone marrow transplant -- often isn t suitable for these very sick patients. Now, an international team of scientists report in Nature Cell Biology on a long-overlooked part of a leukemic cell s internal machinery called the spliceosome, where they found a hyperactive form of a protein called IRAK4 that sends cells on a cancer-causing frenzy.

When they targeted the hyperactive form of IRAK4 in laboratory tests to block its function in AML cells, and in patient AML cells transplanted into immunosuppressed mice, the experimental treatment led to a significant reduction of the leukemic cells. It also prolonged survival in the animal models, according to Daniel Starczynowski, PhD, the multi-institutional study s senior investigator and part of the Cancer and Blood Diseases Institute at Cincinnati Children s Hospital Medical Center.

In this study and other projects in the lab, Starczynowki and colleagues are testing existing drugs that can target hyperactive IRAK4 in leukemia cells. They also are developing a prospective drug that more effectively inhibits hyperactive IRAK4 to treat AML and its precursor disease, myelodysplastic syndromes (MDS).

Starczynowski said that with additional preclinical research and development, the researchers would like within a few years to have their still-unnamed IRAK4 inhibitor ready for initial clinical tests in AML patients. The need for new treatments is urgent, he said.

"There is very little we can do for these patients. Even new drugs now getting fast-tracked through the development process may only produce another six months of survival," Starczynowski said. "The curative option is a bone marrow transplant, but most of these patients don t qualify. The field is really desperate for something that can help these patients."

The findings in this study, including use of IRAK4-inhibiting drugs, would potentially affect a subset of about 20 percent of AML-MDS patients, according to researchers. But that s significant, they say. Now that they know to look more closely at this seemingly obscure, tiny molecular machine in the cell s nucleus -- the spliceosome -- it creates a way to find genetic coding miscues that fuel other subsets of AML that also depend on a hyperactive IRAK4.

Sequencing in the Spliceosome

Although invisible to the naked eye, the spliceosome is important. In a process of dicing and splicing, the spliceosome edits out unnecessary snippets of RNA coding called introns or exons. It then splices the loose snipped ends of RNA back together so specific proteins will do their jobs correctly.

But in AML cells, there are mutations in a gene call U2AF1, which result in RNA splicing errors. When U2AF1 functions normally, the correct snipped ends of RNA are glued back together. But when a mutated form of U2AF1 produces incorrectly formed RNA molecules of IRAK4, it results in a version of IRAK4 protein with extra coding sequences called IRAK4-L (or long). Together they hijack the innate immune system s molecular processes and trigger oncogenesis in myeloid blood cells.

Global Effort

Including first author Molly Smith, a graduate student and member of the Starczynowski lab, the study was a collaboration of eight institutions in the U.S. and the University of Oxford in England. The focus on IRAK4 started over five years ago when Cincinnati Children s cancer biologist Kakajan Komurov -- working on a separate research project -- noticed that every time he analyzed cancerous cells from patients, he saw high levels of the IRAK4 protein with extra coding sequences.

After Komurov shared his observation with Starczynowski during a chance corridor encounter at work, they launched a new project that went on to include Cincinnati Children s bioinformatician Nathan Salomonis, PhD, and Gaurav Choudhary, PhD, and Amit Verma, MD, at the Albert Einstein College of Medicine in Bronx, NY.

Also collaborating are investigators from the National Institutes of Health (NIH), the University of Cincinnati, and the Department of Medicine at Washington University in St. Louis.

Because the preclinical results are from experiments in cell lines and mouse models, the researchers are careful to emphasize their findings may not translate clinically to human patients. Still, the researchers say they re encouraged to have come far enough that the design of new and potentially effective targeted therapies is well underway for a blood cancer that has few such options.

advertisement

Materials provided by . Note: Content may be edited for style and length.

Cincinnati Children s Hospital Medical Center. "Overlooked molecular machine in cell nucleus may hold key to treating aggressive leukemia: Spliceosome misconnects generate mutant gene/protein that fuel cancerous cells." ScienceDaily. ScienceDaily, 22 April 2019. .

Cincinnati Children s Hospital Medical Center. "Overlooked molecular machine in cell nucleus may hold key to treating aggressive leukemia: Spliceosome misconnects generate mutant gene/protein that fuel cancerous cells." ScienceDaily. www.sciencedaily.com/releases/2019/04/190422170536.htm (accessed April 22, 2019).
Read more on sciencedaily.com
News Topics :
RELATED STORIES :
Science
This microscopic image of myeloid cells taken from a genetic mouse model shows signs of the blood disease MDS myelodysplastic syndromes , which can lead to leukemia. Instead of the normal...
Science
Drug resistance is a major obstacle to effective treatment for patients with cancer and leukemia. Epigenetic modifying drugs have been proven effective for some patients with hematologic malignancies, such as...
Science
Researchers from the Albert Einstein College of Medicine in New York have discovered that a signaling protein elevated in patients with acute myeloid leukemia AML plays a much wider role...
Science
Previous research has revealed that patients with acute myeloid leukemia who also have a particular mutation in a gene called NPM1 have a higher rate of remission with chemotherapy. About...
Health
TORONTO Canadian researchers have discovered a pre leukemic stem cell that may be at the root of acute myeloid leukemia and also be the bad actor that evades chemotherapy and...